Detalhe da pesquisa
1.
Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.
Annu Rev Immunol
; 39: 719-757, 2021 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33646859
2.
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
J Allergy Clin Immunol
; 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38272375
3.
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
N Engl J Med
; 385(18): 1656-1668, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706171
4.
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
Eur Respir J
; 63(4)2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38453256
5.
The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
Eur Respir J
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609096
6.
Tezepelumab in patients with allergic and eosinophilic asthma.
Allergy
; 79(5): 1134-1145, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146651
7.
Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study.
Ann Allergy Asthma Immunol
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697286
8.
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control.
J Allergy Clin Immunol
; 152(4): 876-886, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315813
9.
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
Lancet
; 399(10328): 909-923, 2022 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35248186
10.
Living without eosinophils: evidence from mouse and man.
Eur Respir J
; 61(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35953100
11.
European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma.
Eur Respir J
; 62(4)2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37678955
12.
Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status.
Allergy
; 78(8): 2148-2156, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37073882
13.
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
Allergy
; 78(11): 2921-2932, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37431558
14.
Modelling ASthma TrEatment Responses (MASTER): Effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: A time-to-event analysis of randomized clinical trials.
Br J Clin Pharmacol
; 89(11): 3273-3290, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37221636
15.
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Ann Allergy Asthma Immunol
; 130(2): 206-214.e2, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332763
16.
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
Ann Allergy Asthma Immunol
; 130(1): 60-66, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35569802
17.
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
Ann Allergy Asthma Immunol
; 131(5): 587-597.e3, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37619779
18.
The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism.
J Immunol
; 206(11): 2714-2724, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34011519
19.
Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.
J Asthma
; 60(9): 1767-1774, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36876957
20.
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.
Am J Respir Crit Care Med
; 206(5): 545-553, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35549845